3,3′-Diindolylmethane increases serum interferon-γ levels in the K14-HPV16 transgenic mouse model for cervical cancer

In Vivo

Volumn 26, Issue 2, 2012, Pages 207-211

  Sepkovic, Daniel W ^a   Raucci, Laura ^a   Stein, Johann ^a   Carlisle, Antoine D ^a   Auborn, Karen ^b   Ksieski, H Barbara ^a   Nyirenda, Themba ^a   Bradlow, H Leon ^a  

^a HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^b FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

3,3 Diindolylmethane; Cancer prevention; Cervical cancer; Gas chromatography; Interferon ; K14 HPV16 transgenic mouse model; Serum estrogen metabolites

Indexed keywords

3,3' DIINDOLYLMETHANE; ESTROGEN; GAMMA INTERFERON; 2 HYDROXYESTRADIOL; 2-HYDROXYESTRADIOL; 3,3'-DIINDOLYLMETHANE; ANTINEOPLASTIC AGENT; CYTOKERATIN 14; DRUG DERIVATIVE; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; ESTRADIOL; HYBRID PROTEIN; INDOLE DERIVATIVE; KRT14 PROTEIN, HUMAN; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; PROTEIN E7; REPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 16; MOUSE; NONHUMAN; PAPILLOMAVIRUS INFECTION; PROTEIN BLOOD LEVEL; UTERINE CERVIX CANCER; ANIMAL; BIOSYNTHESIS; BLOOD; COMPARATIVE STUDY; EPITHELIUM CELL; GENETICS; METABOLISM; NEOPLASM; ORAL DRUG ADMINISTRATION; PATHOLOGY; PHYSIOLOGY; PROMOTER REGION; SQUAMOUS CELL CARCINOMA; TRANSGENE; TRANSGENIC MOUSE; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX TUMOR;

ADMINISTRATION, ORAL; ANIMALS; ANTICARCINOGENIC AGENTS; CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL CELLS; ESTRADIOL; FEMALE; HUMAN PAPILLOMAVIRUS 16; INDOLES; INTERFERON-GAMMA; KERATIN-14; MICE; MICE, TRANSGENIC; NEOPLASMS, HORMONE-DEPENDENT; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; PROMOTER REGIONS, GENETIC; RECOMBINANT FUSION PROTEINS; REPRESSOR PROTEINS; TRANSGENES; UTERINE CERVICAL NEOPLASMS;

EID: 84857814357     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. U.S. Department of Health and Human Services - National Cancer Institute (NCI): Cancer Incidence - Surveillance, Epidemiology, and End Results (SEER) Registries Research Data. Bethesda, Maryland: National Cancer Institute, Cancer Statistics Branch 2010.
2. Division of STD Prevention. Prevention of Genital HPV Infection and Sequelae: Report of an External Consultants' Meeting. Atlanta, GA: Centers for Disease Control and Prevention, 1999.
3. Sundström K, Eloranta S, Sparén P, Arnheim Dahlström L, Gunnell A, Lindgren A, Palmgren J, Ploner A, Sanjeevi CB, Melbye M, Dillner J, Adami HO and Ylitalo N: Prospective study of human papillomavirus (HPV) types, HPV persistence, and risk of squamous cell carcinoma of the cervix. Cancer Epidemiol Biomarkers Prev 9(70): 2469-2478, 2010.
4. Bell MC, Crowley-Norwick P, Bradlow HL, Sepkovic DW, Baugh S, Howell P, Mayeaux EJ, Tucker A, Turbat-Herrera EA and Mathis JM: Placebo controlled trial of indole-3-carbinol in the treatment of cervical dysplasia. Gynecologic Oncology 78: 123-129, 2000. (Pubitemid 30650341)
5. Yuan F, Chen D, Lui K, Sepkovic DW, Bradlow HL and Auborn K: Anti-estrogen effect of indole-3-carbinol in cervical cancer cells: Implication for prevention of cervical cancer. Anticancer Res 19: 1673-1680, 1999. (Pubitemid 29392722)
6. Sepkovic D W, Bradlow H L and Bell M: Quantitative determination of 3,3′-diindolylmethane In the urine of Individuals receiving indole-3-carbinol. Nutr Cancer 41(1-2): 57-63, 2002.
7. Jin L, Qi M, Chen DZ, Anderson A, Yang GU, Arbiet JM and Auborn, KJ: Indole-3-carbinol prevents cervical cancer in human papilloma virus type 16 transgenic mice. Cancer Research 59: 3991-97, 1999. (Pubitemid 29393567)
8. Sepkovic DW, Stein J, Carlisle AD, Auborn K, Nyirenda T, and Bradlow HL: Early findings from a dose response study using 3, 3′-diindolylmethane in the K14-HPV16 transgenic mouse model: Cervical histology. In: The 2010 Proceedings of ASCO-NCI-EORTC Annual Meeting on Molecular Markers in Cancer, Hollywood Fl. American Society of Clinical Oncology, Abstract #156 pp. 98, 2010.
9. Sepkovic DW, Stein J, Carlisle AD, Ksieski HB, Auborn K and Bradlow HL: Diindolylmethane inhibits cervical dysplasia, alters estrogen metabolism, and enhances immune response in the K14-HPV16 transgenic mouse model. Cancer Epidemiol Biomarkers Prev 18(11): 2957-2964, 2009.
10. Sepkovic DW, Stein J, Carlisle AD, Ksieski HB, Auborn K, Raucci L, Nyirenda T and Bradlow HL: Results from a dose-response study using 3,3′-diindolylmethane in the K14-HPV16 mouse model: Cervical histology. Cancer Prev Res 4(6): 890-896, 2011.
11. Auborn K, Abramson A, Bradlow HL, Sepkovic DW and Mullolly V: Estrogen metabolism and respiratory papillomatosis: A pilot study on dietary prevention. Anticancer Res 18: 4569-4574, 1998.
12. Coll DA Rosen CA, Auborn K, Potsic WP and Bradlow H: Treatment of recurrent respiratory papillomatosis with Indole-3-Carbinol Am J Otolaryngol 18: 283-285, 1997. (Pubitemid 27299240)
13. Meng Q, Goldberg ID, Rosen EM and Fan S: Inhibitory effects of indole-3-carbinol on invasion and migration in human breast cancer cells. Breast Cancer Res Treat 63(2): 147-152, 2000.
14. Mei Q, Anderson AE, Chen DZ, Shishinn S and Auborn KJ: Indole-3-carbinol prevents PTEN loss in cervical cancer in vivo. Mol Med 11(1-12): 59-63, 2005.
15. Riby JE, Xue L, Chatterji U, Bjeldanes EL, Firestone GL and Bjeldanes LF: Activation and potentiation of interferon-(gamma) signaling by 3,3′-diindolylmethane in MCF-7 breast cancer cells. Mol Pharmacol 69(2): 430-439, 2006. (Pubitemid 43121940)
16. Xue L, Pestka J, Maoxiang L, Firestone GL and Bjeldanes LF: 3,3′-Diindolylmethane stimulates murine immune function in vitro and in vivo. Journal of Nutr Biochem 19(5): 336-344, 2008. (Pubitemid 351503766)
17. Arbeit JM, Munger K, Howley PM and Hanahan D: Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice. J Virol 68: 4358-4368, 1994. (Pubitemid 24183029)
18. Arbeit JM, Howley PM and Hanahan D: Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. Proc Natl Acad Sci 93: 2930-2935, 1996. (Pubitemid 26114341)
19. Sepkovic DW, Bradlow HL, Michnovicz J, Murtezani S, Levy I and Osborne MP: Catechol estrogen production in rat microsomes after treatment with indole 3 carbinol, ascorbigen, or β napthaflavone: A comparison of stable isotope dilution gas chromatography mass spectrometry and radiometric methods. Steroids 59: 318-323, 1994.
20. Dehennin L, Reiffsteck A and Scholler R: Simple methods for the synthesis of twenty different highly enriched deuterium labelled steroids suitable as internal standards for isotope dilution mass spectrometry. Biochem Mass Spectr 7: 493-499, 1980. (Pubitemid 11157460)
21. Raju U, Sepkovic DW, Dixon JM, Bradlow HL and Levitz M: Estrone and estradiol metabolism in vivo in human breast cysts. Steroids 65: 883-888, 2000.
22. Dmitrienko A, Tamhane AC and Bretz F: Multiple Testing Problems in Pharmaceutical Statistics. Boca Raton, FL, CRC Press: 2010.
23. Dmitrienko A, Chuang-Stein C and D'Agostino R: Pharmaceutical Statistics Using SAS. A Practical Guide. Cary, NC: SAS Institute Inc: 2007.
24. Chen YI: Nonparametric identification of minimum effective dose. Biometrics 55: 1236-1240, 1999.
25. Smith S, Sepkovic D, Bradlow HL and Auborn KJ:. 3,3′- Diindolylmethane and genistein decrease the adverse effects of estrogen in LNCap and PC-3 prostate cancer cells. J Nutrition 138: 2379-2385, 2008.